HUMANIZED ANTIBODIES SPECIFIC FOR MYELOMA AND OVARIAN CANCER CELLS

The disclosure provides for humanized antibodies, and fragments thereof, that are capable of binding to and killing human myeloma and ovarian cancer cells. The antibodies and their fragments are useful for therapeutic, diagnostic, and research purposes.

Saved in:
Bibliographic Details
Main Author GELBER, Cohava
Format Patent
LanguageEnglish
Published 04.05.2023
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The disclosure provides for humanized antibodies, and fragments thereof, that are capable of binding to and killing human myeloma and ovarian cancer cells. The antibodies and their fragments are useful for therapeutic, diagnostic, and research purposes.
AbstractList The disclosure provides for humanized antibodies, and fragments thereof, that are capable of binding to and killing human myeloma and ovarian cancer cells. The antibodies and their fragments are useful for therapeutic, diagnostic, and research purposes.
Author GELBER, Cohava
Author_xml – fullname: GELBER, Cohava
BookMark eNrjYmDJy89L5WRw8gj1dfTzjHJ1UXD0C_F08nfxdA1WCA5wdfZ083RWcPMPUvCNdPXx93UEyrso-Ic5Bnk6-ik4O_o5uwYpOLv6-ATzMLCmJeYUp_JCaW4GZTfXEGcP3dSC_PjU4oLE5NS81JL40GAjAyNjQ2MLUyMDR0Nj4lQBALNJLZk
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
Physics
ExternalDocumentID US2023138520A1
GroupedDBID EVB
ID FETCH-epo_espacenet_US2023138520A13
IEDL.DBID EVB
IngestDate Fri Jul 19 13:06:58 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_US2023138520A13
Notes Application Number: US202117793603
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230504&DB=EPODOC&CC=US&NR=2023138520A1
ParticipantIDs epo_espacenet_US2023138520A1
PublicationCentury 2000
PublicationDate 20230504
PublicationDateYYYYMMDD 2023-05-04
PublicationDate_xml – month: 05
  year: 2023
  text: 20230504
  day: 04
PublicationDecade 2020
PublicationYear 2023
RelatedCompanies CAERUS THERAPEUTICS, INC
RelatedCompanies_xml – name: CAERUS THERAPEUTICS, INC
Score 3.4640532
Snippet The disclosure provides for humanized antibodies, and fragments thereof, that are capable of binding to and killing human myeloma and ovarian cancer cells. The...
SourceID epo
SourceType Open Access Repository
SubjectTerms BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES
MEASURING
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PHYSICS
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
TESTING
VINEGAR
WINE
Title HUMANIZED ANTIBODIES SPECIFIC FOR MYELOMA AND OVARIAN CANCER CELLS
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230504&DB=EPODOC&locale=&CC=US&NR=2023138520A1
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LS8NAEB5Kfd60KlWrLCi5BZtmY3sJkmw2NNI8aJpSvZQ03YAgaTER_76TpdWeetwZWPY1O9_szgPgES_DPk1pqlKhGSrVc6oO6rPc7-aIDjTRy2VtQD94Hib0dWbMGvC5jYWReUJ_ZHJElKgM5b2S9_X6_xHLkb6V5dPiA0mrF3diOsrGOkY8beCmO7bJo9AJmcKYmcRKMJY8TR8Yva6FttIBAul-LQ98atdxKetdpeKewWGE_RXVOTRE0YITtq291oJjf_Pl3YIj6aOZlUjcyGF5AfYw8a3Ae-cOsYKJZ4c1qiNxxJnneoygZUf8Nz4KfQv5Dgmn1tizAsLqSjRjwvhoFF_Cg8snbKjisOZ_qzBP4t056FfQLFaFaAOhaJQYqdARmmVURrbqvUxbZt2loCmij2vo7OvpZj_7Fk7rpvTxox1oVl_f4g71cLW4l8v3C85Igv0
link.rule.ids 230,309,783,888,25576,76876
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dT8IwEL8Q_MA3RY0fqE00vC0y1gkvxGxdl033QdhG0JdljJKYmEFkxn_fWwPKE693yaW99nq_a-96AA94GPZoRjOFClVXqDanSr_ay73OHNGBKrpz2RvQD56chL5M9EkNPje1MPKf0B_5OSJaVI72Xsrzevl_iWXJ3MrV4_QDSYtnOx5Y7XV0jHhax0W3zAEfhlbI2owNkqgdjCRP1fp6t2NgrLSHILtX2QMfm1VdynLbqdjHsD9EeUV5AjVRNKHBNr3XmnDor5-8m3AgczTzFRLXdrg6BdNJfCNw37lFjCB2zbBCdSQacubaLiMY2RH_jXuhbyDfIuHYGLlGQFjViWZEGPe86AzubR4zR8FhpX9aSJNoew7aOdSLRSEugFAMSvRMaAjNciorW7Vurs7yzkzQDNHHJbR2Sbrazb6DhhP7Xuq5wes1HFUsme9HW1Avv77FDfrkcnorVfkLH1KF8A
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=HUMANIZED+ANTIBODIES+SPECIFIC+FOR+MYELOMA+AND+OVARIAN+CANCER+CELLS&rft.inventor=GELBER%2C+Cohava&rft.date=2023-05-04&rft.externalDBID=A1&rft.externalDocID=US2023138520A1